Developmental and Epileptic Encephalopathy
8
1
3
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
1 terminated out of 8 trials
66.7%
-19.9% vs benchmark
25%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (8)
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy
Developmental and Epileptic Encephalopathies Diagnosed Via Long-read Genome Sequencing
Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Developmental and Epileptic Encephalopathy of Genetic Etiology: Natural History Through Reuse of Clinical Data
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies